IL210003A0 - Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds - Google Patents
Anthracycline derivative conjugates, process for their preparation and their use as antitumor compoundsInfo
- Publication number
- IL210003A0 IL210003A0 IL210003A IL21000310A IL210003A0 IL 210003 A0 IL210003 A0 IL 210003A0 IL 210003 A IL210003 A IL 210003A IL 21000310 A IL21000310 A IL 21000310A IL 210003 A0 IL210003 A0 IL 210003A0
- Authority
- IL
- Israel
- Prior art keywords
- preparation
- anthracycline derivative
- antitumor compounds
- derivative conjugates
- conjugates
- Prior art date
Links
- 229940045799 anthracyclines and related substance Drugs 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8094408P | 2008-07-15 | 2008-07-15 | |
| PCT/US2009/050537 WO2010009124A2 (en) | 2008-07-15 | 2009-07-14 | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL210003A0 true IL210003A0 (en) | 2011-02-28 |
Family
ID=41404334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL210003A IL210003A0 (en) | 2008-07-15 | 2010-12-15 | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8900589B2 (OSRAM) |
| EP (1) | EP2303332B1 (OSRAM) |
| JP (2) | JP6067222B2 (OSRAM) |
| KR (1) | KR101667062B1 (OSRAM) |
| CN (1) | CN102159248B (OSRAM) |
| AR (1) | AR072804A1 (OSRAM) |
| AU (1) | AU2009270988A1 (OSRAM) |
| BR (1) | BRPI0910810A2 (OSRAM) |
| CA (1) | CA2727915C (OSRAM) |
| ES (1) | ES2532635T3 (OSRAM) |
| IL (1) | IL210003A0 (OSRAM) |
| MX (1) | MX2011000509A (OSRAM) |
| PE (1) | PE20110571A1 (OSRAM) |
| RU (1) | RU2523419C2 (OSRAM) |
| SG (1) | SG192517A1 (OSRAM) |
| TW (1) | TWI461428B (OSRAM) |
| WO (1) | WO2010009124A2 (OSRAM) |
| ZA (1) | ZA201009122B (OSRAM) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| ATE509033T1 (de) | 2006-03-20 | 2011-05-15 | Univ California | Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting |
| JP6126773B2 (ja) * | 2007-09-04 | 2017-05-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原（ｐｓｃａ）抗体 |
| WO2009046294A2 (en) * | 2007-10-03 | 2009-04-09 | Cornell University | Treatment of proliferative disorders using antibodies to psma |
| ES2547552T3 (es) * | 2008-02-01 | 2015-10-07 | Genentech, Inc. | Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos |
| KR101667062B1 (ko) * | 2008-07-15 | 2016-10-17 | 제넨테크, 인크. | 안트라시클린 유도체 접합체, 그의 제조 방법 및 항-종양 화합물로서의 그의 용도 |
| US20100069616A1 (en) * | 2008-08-06 | 2010-03-18 | The Regents Of The University Of California | Engineered antibody-nanoparticle conjugates |
| ES2712732T3 (es) * | 2009-02-17 | 2019-05-14 | Cornell Res Foundation Inc | Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico |
| AU2010325969B2 (en) | 2009-12-02 | 2016-10-20 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen |
| WO2011106297A2 (en) | 2010-02-23 | 2011-09-01 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US9725500B2 (en) | 2010-03-02 | 2017-08-08 | Seattle Genetics, Inc. | Methods for screening antibodies |
| SMT201900549T1 (it) | 2010-03-12 | 2019-11-13 | Debiopharm Int Sa | Molecole leganti il cd37 e loro immunoconiugati |
| WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
| AU2011320314B2 (en) | 2010-10-29 | 2015-08-06 | Immunogen, Inc. | Novel EGFR-binding molecules and immunoconjugates thereof |
| AU2011320318B9 (en) | 2010-10-29 | 2015-11-19 | Immunogen, Inc. | Non-antagonistic EGFR-binding molecules and immunoconjugates thereof |
| BR112013013127B1 (pt) | 2010-12-02 | 2021-06-22 | Nerviano Medical Sciences S.R.L. | Processo para a preparação de derivados de morfolinil antraciclina, compostos derivados de morfolinil antraciclina e composição farmacêutica compreendendo estes compostos |
| EP3296321B1 (en) | 2010-12-20 | 2020-07-15 | F. Hoffmann-La Roche AG | Anti-mesothelin antibodies and immunoconjugates |
| EA201391342A1 (ru) | 2011-04-01 | 2014-11-28 | Иммьюноджен, Инк. | Cd37-связывающие молекулы и их иммуноконъюгаты |
| EP2592103A1 (en) | 2011-11-08 | 2013-05-15 | Adriacell S.p.A. | Polymer aldehyde derivatives |
| SG11201402343SA (en) | 2011-11-21 | 2014-06-27 | Immunogen Inc | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
| CA2857398A1 (en) * | 2011-12-05 | 2013-06-13 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
| WO2013109994A1 (en) | 2012-01-20 | 2013-07-25 | Sea Lane Biotechnologies, Llc | Surrobody cojugates |
| EP2822597A1 (en) * | 2012-03-09 | 2015-01-14 | UCL Business Plc. | Chemical modification of antibodies |
| AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| US9561290B2 (en) | 2012-04-05 | 2017-02-07 | Nerviano Medical Sciences S.R.L. | Functionalized thieno-indole derivatives for the treatment of cancer |
| US9527863B2 (en) | 2012-04-05 | 2016-12-27 | Nerviano Medical Sciences S.R.L. | Thieno-indole moieties and methods of treating using the same |
| SG11201407106XA (en) | 2012-05-01 | 2014-11-27 | Genentech Inc | Anti-pmel17 antibodies and immunoconjugates |
| CN104736179B (zh) * | 2012-05-07 | 2017-09-26 | 日东电工株式会社 | 具有接头的聚合物缀合物 |
| US9981046B2 (en) | 2012-05-15 | 2018-05-29 | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. | Drug-conjugates, conjugation methods, and uses thereof |
| TWI614265B (zh) | 2012-05-21 | 2018-02-11 | 建南德克公司 | 抗－Ｌｙ６Ｅ抗體及免疫結合物及其使用方法 |
| TW201408696A (zh) * | 2012-07-09 | 2014-03-01 | Genentech Inc | 抗ｃｄ２２抗體及免疫結合物 |
| HK1207972A1 (en) * | 2012-07-09 | 2016-02-19 | 基因泰克公司 | Immunoconjugates comprising anti - cd79b antibodies |
| RU2015106946A (ru) * | 2012-08-02 | 2016-09-27 | Дженентек, Инк. | Антитела к рецептору эндотелина типа в (etbr) и их иммуноконъюгаты |
| CN104717979A (zh) | 2012-08-02 | 2015-06-17 | 基因泰克公司 | 抗etbr抗体和免疫偶联物 |
| RU2015120074A (ru) | 2012-10-30 | 2016-12-20 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Функционализированные производные 9-бром-камптотецина |
| WO2014124316A2 (en) * | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| KR20150127199A (ko) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | 항-b7-h4 항체 및 면역접합체 |
| EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| EP2991993B1 (en) * | 2013-04-29 | 2018-06-06 | Nerviano Medical Sciences S.r.l. | Morpholinyl anthracycline derivatives |
| GB201309807D0 (en) | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
| TWI725931B (zh) * | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| AU2014293013A1 (en) | 2013-07-26 | 2016-03-17 | Race Oncology Ltd. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| LT3041507T (lt) | 2013-08-26 | 2021-08-25 | Biontech Research And Development, Inc. | Nukleorūgštys, koduojančios antikūnus prieš sialil-lewis a |
| HK1218124A1 (zh) | 2013-09-17 | 2017-02-03 | 豪夫迈．罗氏有限公司 | 使用抗lgr5抗体的方法 |
| ES2738657T3 (es) | 2013-09-25 | 2020-01-24 | Nerviano Medical Sciences Srl | Derivados de tieno[2,3-e]indol como nuevos antitumorales |
| CA2934030A1 (en) | 2013-10-15 | 2015-04-23 | Sorrento Therapeutics Inc. | Drug-conjugates with a targeting molecule and two different drugs |
| KR20160068963A (ko) | 2013-10-21 | 2016-06-15 | 제넨테크, 인크. | 항-Ly6E 항체 및 사용 방법 |
| TW201533060A (zh) | 2013-12-13 | 2015-09-01 | Genentech Inc | 抗ｃｄ３３抗體及免疫結合物 |
| CN105873614B (zh) * | 2013-12-16 | 2020-10-30 | 基因泰克公司 | 肽模拟化合物及其抗体-药物缀合物 |
| EP3736292B1 (en) | 2013-12-17 | 2024-05-08 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| US10300070B2 (en) | 2014-03-27 | 2019-05-28 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
| WO2015179658A2 (en) | 2014-05-22 | 2015-11-26 | Genentech, Inc. | Anti-gpc3 antibodies and immunoconjugates |
| CA3121083C (en) | 2014-06-04 | 2023-08-15 | Biontech Research And Development, Inc. | Human monoclonal antibodies to ganglioside gd2 |
| KR102557615B1 (ko) | 2014-06-06 | 2023-07-20 | 레드우드 바이오사이언스 인코포레이티드 | 항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법 |
| ES3034398T3 (en) | 2014-08-28 | 2025-08-18 | Bioatla Inc | Conditionally active chimeric antigen receptors for modified t-cells |
| SG11201701623UA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Anti-her2 antibodies and immunoconjugates |
| JP6943760B2 (ja) | 2014-09-12 | 2021-10-06 | ジェネンテック， インコーポレイテッド | 抗ｂ７−ｈ４抗体及び免疫複合体 |
| EA201790569A1 (ru) | 2014-09-12 | 2017-08-31 | Дженентек, Инк. | Антитела и иммуноконъюгаты против cll-1 |
| BR112017003236A2 (pt) | 2014-09-12 | 2017-11-28 | Genentech Inc | anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica |
| US10149913B2 (en) | 2014-09-12 | 2018-12-11 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| GB201419108D0 (en) * | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
| EP3215513B1 (en) * | 2014-11-05 | 2019-05-08 | Nerviano Medical Sciences S.r.l. | Functionalized morpholinyl anthracycline derivatives |
| WO2016090050A1 (en) * | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
| CA2971634C (en) | 2014-12-23 | 2024-06-04 | Nbe-Therapeutics Ag | Binding protein drug conjugates comprising anthracycline derivatives |
| ES2918425T3 (es) | 2015-01-28 | 2022-07-15 | Sorrento Therapeutics Inc | Conjugados de anticuerpo-fármaco |
| US20170224835A1 (en) * | 2015-02-06 | 2017-08-10 | Sorrento Therapeutics, Inc. | Antibody Drug Conjugates |
| MX392539B (es) | 2015-06-08 | 2025-03-24 | Debiopharm Int Sa | Combinaciones de inmunoconjugado anti-cd37 y anticuerpo anti-cd20. |
| US10323094B2 (en) | 2015-06-16 | 2019-06-18 | Genentech, Inc. | Humanized and affinity matured antibodies to FcRH5 and methods of use |
| CN115960230A (zh) | 2015-08-07 | 2023-04-14 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
| UA129489C2 (uk) | 2015-08-28 | 2025-05-14 | Дебіофарм Інтернаціонал, С.А. | Антитіло до cd37 |
| US11332543B2 (en) | 2015-10-05 | 2022-05-17 | Fredax Ab | Antibody polypeptides and uses thereof |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| EP3165237B1 (en) | 2015-11-03 | 2018-12-19 | Industrial Technology Research Institute | Antibody-drug conjugate (adc) and method for forming the same |
| US11173214B2 (en) * | 2015-11-25 | 2021-11-16 | Legochem Biosciences, Inc. | Antibody-drug conjugates comprising branched linkers and methods related thereto |
| US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
| AU2017211120C1 (en) * | 2016-01-25 | 2021-10-07 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| CA3016474A1 (en) | 2016-03-15 | 2017-09-21 | Mersana Therapeutics, Inc. | Napi2b-targeted antibody-drug conjugates and methods of use thereof |
| US20170315132A1 (en) * | 2016-03-25 | 2017-11-02 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
| WO2017180842A1 (en) | 2016-04-15 | 2017-10-19 | Bioatla, Llc | Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof |
| CN109311987A (zh) | 2016-05-13 | 2019-02-05 | 生物蛋白有限公司 | 抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途 |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| EP3465221B1 (en) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
| EP3464294B1 (en) | 2016-05-30 | 2022-07-13 | Toxinvent Oü | Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment |
| EP3475264A4 (en) | 2016-06-28 | 2020-04-15 | University Of Kentucky Research Foundation | PROSTAGLANDIN E SYNTHASE INHIBITORS AND METHODS OF USE |
| US11278629B2 (en) | 2016-11-02 | 2022-03-22 | Debiopharm International, S.A. | Methods for improving anti-CD37 immunoconjugate therapy |
| KR102532256B1 (ko) | 2016-11-21 | 2023-05-12 | 쿠레아브 게엠베하 | 항-gp73 항체 및 면역접합체 |
| WO2018103739A1 (zh) * | 2016-12-09 | 2018-06-14 | 凯惠科技发展(上海)有限公司 | 抗体药物偶联物、制备方法、中间体、药物组合物及应用 |
| WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
| JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
| CA3067829A1 (en) | 2017-06-23 | 2018-12-27 | VelosBio Inc. | Ror1 antibody immunoconjugates |
| IL273252B2 (en) | 2017-09-20 | 2024-03-01 | Mersana Therapeutics Inc | Compositions and methods for predicting response to napi2b-targeted therapy |
| JP7256796B2 (ja) | 2017-10-13 | 2023-04-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体 |
| CN112218662A (zh) | 2018-05-30 | 2021-01-12 | 德彪发姆国际有限公司 | 抗cd37免疫缀合物给药方案 |
| WO2020013803A1 (en) * | 2018-07-09 | 2020-01-16 | Synthis, Llc | Antibody-alk5 inhibitor conjugates and their uses |
| JP2021532116A (ja) * | 2018-07-23 | 2021-11-25 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | 同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用 |
| CN113194999A (zh) | 2018-08-17 | 2021-07-30 | 梅尔莎纳医疗公司 | NaPi2b靶向的聚合物抗体-药物缀合物及其使用方法 |
| WO2020245229A1 (en) | 2019-06-03 | 2020-12-10 | Synaffix B.V. | Acetal-based cleavable linkers |
| CN114206392A (zh) * | 2019-06-10 | 2022-03-18 | 苏特罗生物制药公司 | 免疫调节剂抗体药物偶联物及其用途 |
| GB201908886D0 (en) * | 2019-06-20 | 2019-08-07 | Almac Discovery Ltd | Anthracycline derivatives |
| IL299860A (en) | 2020-07-21 | 2023-03-01 | Genentech Inc | Antibody-conjugated chemical factors for the discharge of BRM and their methods |
| WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| PE20231561A1 (es) | 2020-12-23 | 2023-10-03 | Sotio Biotech A S | Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2 |
| JP7731066B2 (ja) * | 2020-12-25 | 2025-08-29 | パナソニックＩｐマネジメント株式会社 | 作物収量向上剤、及び、作物収量向上方法 |
| CN112924665B (zh) * | 2021-02-19 | 2023-10-03 | 山东莱博生物科技有限公司 | 一种抗体辣根过氧化物酶标记物及其制备与应用 |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| EP4180061A1 (en) | 2021-11-10 | 2023-05-17 | Nerviano Medical Sciences S.r.l. | Anthracycline derivative linker reagents, antibody-drug conjugates and methods |
| AR128331A1 (es) | 2022-01-26 | 2024-04-17 | Genentech Inc | Inductores químicos de degradación conjugados con anticuerpos y métodos de estos |
| AR128330A1 (es) | 2022-01-26 | 2024-04-17 | Genentech Inc | Inductores químicos de degradación conjugados con anticuerpo y métodos de estos |
| TW202525277A (zh) * | 2023-08-10 | 2025-07-01 | 瑞典商阿斯特捷利康公司 | 蒽環黴素衍生物和綴合物及其用途 |
| WO2025168481A1 (en) | 2024-02-05 | 2025-08-14 | Nerviano Medical Sciences S.R.L. | Imino-anthracycline derivatives and methods |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5162512A (en) | 1982-03-09 | 1992-11-10 | Cytogen Corporation | Amine derivatives of anthracycline antibodies |
| US4826964A (en) | 1982-07-20 | 1989-05-02 | Sri International | Bridged oxygen analogs of daunorubcin and doxorubicin |
| GB2172594B (en) | 1985-03-22 | 1988-06-08 | Erba Farmitalia | New morpholino derivatives of daunorubicin and doxorubicin |
| US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
| FI102355B (fi) * | 1988-02-11 | 1998-11-30 | Squibb Bristol Myers Co | Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjug aattien valmistamiseksi |
| CA2016584C (en) * | 1989-05-17 | 1999-06-29 | Robert S. Greenfield | Anthracycline conjugates having a novel linker and methods for their production |
| US5304687A (en) | 1989-12-19 | 1994-04-19 | Farmitalia Carlo Erba S.R.L. | Morpholinyl derivatives of doxorubicin and process for their preparation |
| GB9017024D0 (en) | 1990-08-03 | 1990-09-19 | Erba Carlo Spa | New linker for bioactive agents |
| GB9019933D0 (en) | 1990-09-12 | 1990-10-24 | Erba Carlo Spa | 13-dihydro-3'-(2-alkoxy-4-morphlinyl)anthracyclines |
| CA2048089A1 (en) | 1990-09-17 | 1992-03-18 | Wolfgang A. Wrasidlo | Chemical conjugation of morpholino anthracyclines to antibodies |
| US5776458A (en) | 1990-12-05 | 1998-07-07 | Pharmacia & Upjohn S.P.A. | Anthracycline-conjugates |
| GB9026491D0 (en) * | 1990-12-05 | 1991-01-23 | Erba Carlo Spa | Anthracycline-conjugates |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
| WO1993021319A1 (en) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
| DE69326937T2 (de) | 1993-03-24 | 2000-12-28 | Berlex Biosciences, Richmond | Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung |
| GB2296495B (en) | 1994-12-23 | 1998-04-15 | Erba Carlo Spa | Anthracycline derivatives |
| JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
| MX9800684A (es) | 1995-07-27 | 1998-04-30 | Genentech Inc | Formulacion de proteinas liofilizadas isotonicas estables. |
| US5843903A (en) | 1995-11-27 | 1998-12-01 | The Administrators Of The Tulane Educational Fund | Targeted cytotoxic anthracycline analogs |
| GB2315067B (en) * | 1996-07-11 | 2000-02-16 | Pharmacia Spa | Morpholinyl anthracycline derivatives |
| US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| JP4689781B2 (ja) | 1998-09-03 | 2011-05-25 | 独立行政法人科学技術振興機構 | アミノ酸輸送蛋白及びその遺伝子 |
| NZ502058A (en) | 1999-12-23 | 2003-11-28 | Ovita Ltd | Isolated mutated nucleic acid molecule for regulation of ovulation rate |
| PT1242438E (pt) | 1999-12-29 | 2007-02-28 | Immunogen Inc | Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico |
| JP2005506033A (ja) | 2000-10-13 | 2005-03-03 | イーオーエス バイオテクノロジー インコーポレイテッド | 前立腺癌の診断法、前立腺癌モジュレータースクリーニングの組成物及び方法 |
| AU2002243495A1 (en) | 2001-01-12 | 2002-07-24 | University Of Medicine And Dentistry Of New Jersey | Bone morphogenetic protein-2 in the treatment and diagnosis of cancer |
| JP2005503760A (ja) | 2001-01-24 | 2005-02-10 | プロテイン デザイン ラブス， インコーポレイテッド | 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法 |
| US20040170994A1 (en) | 2001-02-12 | 2004-09-02 | Callen David Frederick | DNA sequences for human tumour suppressor genes |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| WO2002078524A2 (en) | 2001-03-28 | 2002-10-10 | Zycos Inc. | Translational profiling |
| AU2002309583A1 (en) | 2001-04-18 | 2002-11-05 | Protein Desing Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| AU2002314901A1 (en) | 2001-06-04 | 2002-12-16 | Eos Biotechnology, Inc. | Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer |
| JP2004528046A (ja) | 2001-06-05 | 2004-09-16 | エクセリクシス・インコーポレイテッド | ｐ５３経路のモディファイヤーとしてのＤＧＫｓおよび使用方法 |
| ATE483976T1 (de) | 2001-06-05 | 2010-10-15 | Exelixis Inc | Gfats als modifikatoren des p53-wegs und verwendungsverfahren |
| WO2002102235A2 (en) | 2001-06-18 | 2002-12-27 | Eos Biotechnology Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US20050107595A1 (en) | 2001-06-20 | 2005-05-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
| US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
| WO2003016475A2 (en) | 2001-08-14 | 2003-02-27 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
| JP2005518782A (ja) | 2001-09-17 | 2005-06-30 | プロテイン デザイン ラブス， インコーポレイテッド | ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法 |
| EP2153843B1 (en) | 2001-09-18 | 2012-08-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| AU2002362454A1 (en) | 2001-10-03 | 2003-04-14 | Origene Technologies, Inc. | Regulated breast cancer genes |
| RU2336902C2 (ru) | 2001-10-31 | 2008-10-27 | Алькон, Инк. | Морфогенные белки кости (вмр), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы |
| WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| US20030134790A1 (en) | 2002-01-11 | 2003-07-17 | University Of Medicine And Dentistry Of New Jersey | Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer |
| US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
| US20030224454A1 (en) | 2002-05-30 | 2003-12-04 | Ryseck Rolf Peter | Human solute carrier family 7, member 11 (hSLC7A11) |
| WO2004032842A2 (en) | 2002-10-04 | 2004-04-22 | Van Andel Research Institute | Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers |
| AU2003298786A1 (en) | 2002-11-26 | 2004-06-18 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| US20050227301A1 (en) | 2003-01-10 | 2005-10-13 | Polgen | Cell cycle progression proteins |
| US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| AU2004222526A1 (en) | 2003-03-18 | 2004-09-30 | Pharmacia Italia S.P.A. | Nemorubicin as radiosensitizer in combination with radiation therapy against tumors |
| BRPI0408518A (pt) | 2003-03-18 | 2006-03-07 | Pharmacia Italia Spa | terapia combinada compreendendo nemorubicin e um inibidor de ciclooxigenase-2 |
| CN1897970A (zh) | 2003-06-30 | 2007-01-17 | 生物技术通用（以色列）有限公司 | 特异人抗体 |
| SG149815A1 (en) | 2003-11-06 | 2009-02-27 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| TR201808537T4 (tr) * | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| US20070060534A1 (en) | 2005-06-30 | 2007-03-15 | Threshold Pharmaceuticals, Inc. | Anthracycline analogs |
| LT1912671T (lt) | 2005-07-18 | 2017-12-11 | Seattle Genetics, Inc. | Vaisto konjugatai, turintys gliukoronido linkerį |
| AU2008251608B2 (en) | 2007-05-08 | 2014-03-27 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
| ES2547552T3 (es) * | 2008-02-01 | 2015-10-07 | Genentech, Inc. | Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos |
| KR101667062B1 (ko) * | 2008-07-15 | 2016-10-17 | 제넨테크, 인크. | 안트라시클린 유도체 접합체, 그의 제조 방법 및 항-종양 화합물로서의 그의 용도 |
| BR112013013127B1 (pt) * | 2010-12-02 | 2021-06-22 | Nerviano Medical Sciences S.R.L. | Processo para a preparação de derivados de morfolinil antraciclina, compostos derivados de morfolinil antraciclina e composição farmacêutica compreendendo estes compostos |
-
2009
- 2009-07-14 KR KR1020117003368A patent/KR101667062B1/ko not_active Expired - Fee Related
- 2009-07-14 BR BRPI0910810A patent/BRPI0910810A2/pt not_active IP Right Cessation
- 2009-07-14 AR ARP090102664A patent/AR072804A1/es unknown
- 2009-07-14 RU RU2011105402/15A patent/RU2523419C2/ru active IP Right Revival
- 2009-07-14 WO PCT/US2009/050537 patent/WO2010009124A2/en not_active Ceased
- 2009-07-14 CN CN2009801359822A patent/CN102159248B/zh not_active Expired - Fee Related
- 2009-07-14 TW TW098123764A patent/TWI461428B/zh not_active IP Right Cessation
- 2009-07-14 EP EP09790394.2A patent/EP2303332B1/en active Active
- 2009-07-14 CA CA2727915A patent/CA2727915C/en active Active
- 2009-07-14 MX MX2011000509A patent/MX2011000509A/es active IP Right Grant
- 2009-07-14 SG SG2013053939A patent/SG192517A1/en unknown
- 2009-07-14 US US12/502,433 patent/US8900589B2/en active Active
- 2009-07-14 PE PE2011000027A patent/PE20110571A1/es not_active Application Discontinuation
- 2009-07-14 AU AU2009270988A patent/AU2009270988A1/en not_active Abandoned
- 2009-07-14 ES ES09790394.2T patent/ES2532635T3/es active Active
- 2009-07-14 JP JP2011518840A patent/JP6067222B2/ja not_active Expired - Fee Related
-
2010
- 2010-12-15 IL IL210003A patent/IL210003A0/en unknown
- 2010-12-20 ZA ZA2010/09122A patent/ZA201009122B/en unknown
-
2012
- 2012-01-27 US US13/360,212 patent/US8389697B2/en not_active Expired - Fee Related
-
2014
- 2014-10-30 US US14/528,142 patent/US9695240B2/en not_active Expired - Fee Related
-
2015
- 2015-06-03 JP JP2015113517A patent/JP2016006045A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2532635T3 (es) | 2015-03-30 |
| TWI461428B (zh) | 2014-11-21 |
| CA2727915A1 (en) | 2010-01-21 |
| SG192517A1 (en) | 2013-08-30 |
| JP2016006045A (ja) | 2016-01-14 |
| WO2010009124A2 (en) | 2010-01-21 |
| AU2009270988A1 (en) | 2010-01-21 |
| US8389697B2 (en) | 2013-03-05 |
| HK1157660A1 (en) | 2012-07-06 |
| CN102159248A (zh) | 2011-08-17 |
| KR101667062B1 (ko) | 2016-10-17 |
| US8900589B2 (en) | 2014-12-02 |
| WO2010009124A3 (en) | 2010-12-23 |
| CN102159248B (zh) | 2013-09-11 |
| US20120130059A1 (en) | 2012-05-24 |
| PE20110571A1 (es) | 2011-08-29 |
| RU2523419C2 (ru) | 2014-07-20 |
| EP2303332A2 (en) | 2011-04-06 |
| JP6067222B2 (ja) | 2017-01-25 |
| RU2011105402A (ru) | 2012-08-20 |
| MX2011000509A (es) | 2011-04-05 |
| AR072804A1 (es) | 2010-09-22 |
| ZA201009122B (en) | 2012-03-28 |
| KR20110040922A (ko) | 2011-04-20 |
| TW201011041A (en) | 2010-03-16 |
| JP2011528360A (ja) | 2011-11-17 |
| US9695240B2 (en) | 2017-07-04 |
| US20100034837A1 (en) | 2010-02-11 |
| US20150051380A1 (en) | 2015-02-19 |
| EP2303332B1 (en) | 2014-12-31 |
| BRPI0910810A2 (pt) | 2019-09-24 |
| CA2727915C (en) | 2016-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201009122B (en) | Anthracycline derivative conjugates,process for their preparation and their use as antitumor compounds | |
| IL217208A (en) | History of cryptophycin, critophycin conjugates, processes for their preparation, and their use as anticancer agents | |
| IL211180B (en) | Attached polyethylene glycol and docetaxel | |
| IL206765A0 (en) | 4,5-dihydro-oxazol-2-yl-amine derivatives | |
| IL213595A0 (en) | Oligosaccharide-protein conjugates | |
| IL219735A0 (en) | Conjugate molecule | |
| ZA201102315B (en) | 7-piperidinoalkyl-3,4-dihyfroquinolone derivative | |
| IL213920A0 (en) | 3,3'-spiroindolinone derivatives as anticancer agents | |
| PT2099738T (pt) | Procedimento para produção de polieteraminas | |
| PL2213654T3 (pl) | Sposób wytwarzania pochodnych 2-amino-5-bromobenzamidu | |
| SI2340271T1 (sl) | Konjugati polimer-bioaktivnega sredstva | |
| IL208065A0 (en) | Glucopyranoside derivatives | |
| ZA201008053B (en) | Substituted 2-phenyl-pyridine derivatives | |
| EP2421878A4 (en) | ANIONIC OLIGOSACCHARIDE CONJUGATES | |
| EP2510825B8 (en) | Rotary draw bar | |
| IL209337A0 (en) | Conjugates of a cholinesterase moiety and a polymer, compositions, comprising the same and processes for the preparation of the same | |
| ZA201007615B (en) | Aminopyridine derivatives | |
| IL207263A0 (en) | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | |
| GB0810894D0 (en) | Conjugated saccharide | |
| IL199718A0 (en) | Peptide-complement conjugates | |
| AU2014200012A1 (en) | N-alkoxyamide conjugates as imaging agents | |
| ZA201005346B (en) | 3,8-diaminotetrahydroquinoline derivative | |
| EP2321330B8 (de) | Verfahren zur herstellung phosphatverbrückter nucleosid-konjugate | |
| IL219623A0 (en) | [1,5]-diazocin derivatives | |
| TH0901003178A (th) | คอนจูเกตอนุพันธ์แอนธราไซคลีน, กระบวนการสำหรับเตรียมพวกมันและการใช้พวกมันเป็นสารประกอบต้านเนื้องอก |